Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic
- 25 February 2021
- journal article
- review article
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (5), 508-518
- https://doi.org/10.1159/000514071
Abstract
The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been first described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever since. Initial clinical data imply that cancer patients are particularly at risk for a severe course of SARS-CoV-2. In patients with chronic lymphocytic leukemia (CLL), infections are a main contributor to morbidity and mortality driven by an impaired immune system. Treatment initiation is likely to induce immune modulation that further increases the risk for severe infections. This article aims to give an overview on pathogenesis and risk of infectious complications in patients with CLL. In this context, we discuss current data of SARS-CoV-2 infections in patients with CLL and how the pandemic impacts their management.Keywords
This publication has 89 references indexed in Scilit:
- The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammationHaematologica, 2013
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemiaBlood, 2011
- Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patientsJournal of Translational Medicine, 2010
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Human Platelets AttenuateAspergillusSpecies via Granule‐Dependent MechanismsThe Journal of Infectious Diseases, 2008
- Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemiaClinical and Laboratory Haematology, 2008
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- Treatment of hypogammaglobulinemia in chronic lymphocytic leukaemia by low‐dose intravenous gammaglobulinEuropean Journal of Haematology, 1994
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 1988